Ann: Quarterly Report and Appendix 4C, page-103

You're talking about how they're investing tens of millions in Aus medical marijuana, where did you read that? In the quarterly report they have about $5m of investing expenses, but they explained that that was for expanding the supply side in the US operations. The rest of the expenses are just operational/staff, and if the previous quarterly and its growing revenue is anything to go by, will be covered just fine. The full year results show the Aus medical marijuana operations are costing very little, just a few staff to manage the applications. I see no indication that anything has changed there.

Elixinol seems to be doing exactly what you're suggesting. Focusing on expanding US and overseas operations, that's where the investments are going. They're not really spending anything here, just getting their foot in the door ready for when things finally do start moving along.

This is a hemp focused company that's just keeping an eye on the medical stuff, but their investments and operations and firmly on the hemp side of things. And it seems to be doing just fine, can't wait for the next quarterly!